Renin Angiotensin System Study (RASS/B-RASS)

NCT ID: NCT00143949

Last Updated: 2008-11-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 285 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1997-03-31
• Study Completion Date: 2008-05-31

Brief Summary

To determine if renin angiotensin medications can prevent or delay the onset of diabetic kidney disease.

Detailed Description

The primary objective of this research is to determine, in type 1 (insulin-dependent) diabetic patients without hypertension, diabetic nephropathy (DN), or levels of microalbuminuria (MA) predictive of underlying, already established serious lesion of diabetic nephropathy, if inhibition of renin-angiotensin system (RAS) activity can prevent or retard the rate of development of the histologic lesions associated with DN. This primary prevention study is designed to examine the effect of pharmacologic intervention on the earliest stages of diabetic kidney disease. At the stage of overt DN intervention studies have shown only a slowing, as opposed to arrest, in disease progression, and benefit a minority of treated patients. At the MA stage the renal lesions of DN are already usually firmly established; moreover, progression in MA patients may occur despite strict glycemic or anti-hypertensive control. Renal histologic change over time has been selected as the primary endpoint in order to study the early stages of this disease, since the time to functional endpoints from these earlier stages precludes practical study design.

Specific Aim 1 To recruit 285 type 1 diabetic patients who do not have hypertension, diabetic nephropathy, or predictive levels of microalbuminuria into a 5-year study to determine the effect of inhibition of renin-angiotensin system activity with either losartan (angiotensin II blocker) or enalapril (converting enzyme inhibitor) on the development of diabetic renal disease. This aim has been accomplished and the study is entitled the Renin-Angiotension System Study (RASS).

Specific Aim 2 To obtain two percutaneous renal biopsies from each patient, the first, at entry into the study, and the second after five years of drug therapy with either losartan or enalapril.

Hypothesis Reduction of renin-angiotensin system activity will prevent or retard the development of histologic change in the kidney associated with diabetic nephropathy.

A secondary objective of this study is to evaluate retinal lesions in the RASS cohort of patients in order to determine the relationship of these findings to the histologic changes of DN and to examine the effects of RAS inhibition and/or systemic blood pressure (BP) on the development and progression of diabetic retinopathy. This ancillary study has the following aims:

Specific Aim To obtain baseline, 2.5 and 5 year retinal fundus photographs in the RASS patients.

Hypothesis Cross-sectional and longitudinal relationships of retinal and renal structural abnormalities will emerge which will improve the predictive value of renal functional tests. Reduction of rennin-angiotensin system activity will prevent or retard the development of diabetic retinal lesions

Conditions

Type 1 Diabetes

Keywords

diabetes; nephropathy; kidney; retinopathy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Blinding Strategy: QUADRUPLE

Interventions

enalapril

Intervention Type: DRUG

losartan

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• type 1 diabetic (DM) for 2-20 yrs
• type 1 DM onset prior to 45; if onset was between ages 31-41, BMI <26; onset 41-45, positive GAD or ICA required
• normal or increased GFR
• normal BP
• normoalbuminuric (<20 ug/min on 2 of 3 time overnight urine collections)

Exclusion Criteria

• type 1 DM duration longer than 20 yrs
• hypertension (>85/135 mmHg)
• reduced GFR (<90 ml/min/1.73m2)
• microalbuminuria
• solitary kidney or evidence of unilateral renal disease
• evidence of other important kidney disease by history, ultrasound or biopsy
• other chronic diseases or conditions such as cystic fibrosis, serious mental illness, severe mental retardation, etc.
• pregnancy or females planning pregnancy within 2 years were excluded due to the drugs being used
• compliance (pt not taking at least 85% of two week placebo were excluded)

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 61 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

Sponsor Role: collaborator

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role: collaborator

Merck Frosst Canada Ltd.

INDUSTRY

Sponsor Role: collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

Sponsor Role: collaborator

Michael Mauer, MD

INDIV

Sponsor Role: lead

Principal Investigators

S M Mauer, MD

Role: PRINCIPAL_INVESTIGATOR

University of Minnesota

Locations

Mt Sinai Hospital, University of Toronto (Clinical Ctr)

Toronto, Ontario, Canada

Royal Victoria Hospital, McGill University (Data Center)

Montreal, Quebec, Canada

Montreal Childrens Hospital, McGill University (Clinical Ctr)

Montreal, Quebec, Canada

Countries

Canada

References

Mauer M, Zinman B, Gardiner R, Drummond KN, Suissa S, Donnelly SM, Strand TD, Kramer MS, Klein R, Sinaiko AR. ACE-I and ARBs in early diabetic nephropathy. J Renin Angiotensin Aldosterone Syst. 2002 Dec;3(4):262-9. doi: 10.3317/jraas.2002.048.

Reference Type: BACKGROUND

PMID: 12584670 (View on PubMed)

Limonte CP, Prince DK, Hoofnagle AN, Galecki A, Hirsch IB, Tian F, Waikar SS, Looker HC, Nelson RG, Doria A, Mauer M, Kestenbaum BR, de Boer IH. Associations of Biomarkers of Tubular Injury and Inflammation with Biopsy Features in Type 1 Diabetes. Clin J Am Soc Nephrol. 2024 Jan 1;19(1):44-55. doi: 10.2215/CJN.0000000000000333. Epub 2023 Oct 23.

Reference Type: DERIVED

PMID: 37871959 (View on PubMed)

Robiner WN, Strand TD, Mauer M; Renin Angiotensin System Study (RASS) Group. Adherence and renal biopsy feasibility in the Renin Angiotensin-System Study (RASS) primary prevention diabetes trial. Diabetes Res Clin Pract. 2013 Oct;102(1):25-34. doi: 10.1016/j.diabres.2013.06.004. Epub 2013 Sep 17.

Reference Type: DERIVED

PMID: 24050942 (View on PubMed)

Harindhanavudhi T, Mauer M, Klein R, Zinman B, Sinaiko A, Caramori ML; Renin Angiotensin System Study (RASS) group. Benefits of Renin-Angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control. Diabetes Care. 2011 Aug;34(8):1838-42. doi: 10.2337/dc11-0476. Epub 2011 Jun 29.

Reference Type: DERIVED

PMID: 21715517 (View on PubMed)

Klein R, Myers CE, Klein BE, Zinman B, Gardiner R, Suissa S, Sinaiko AR, Donnelly SM, Goodyer P, Strand T, Mauer M. Relationship of blood pressure to retinal vessel diameter in type 1 diabetes mellitus. Arch Ophthalmol. 2010 Feb;128(2):198-205. doi: 10.1001/archophthalmol.2009.391.

Reference Type: DERIVED

PMID: 20142543 (View on PubMed)

Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, Goodyer P, Gubler MC, Klein R. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009 Jul 2;361(1):40-51. doi: 10.1056/NEJMoa0808400.

Reference Type: DERIVED

PMID: 19571282 (View on PubMed)

Other Identifiers

9601M10705

Identifier Type: -

Identifier Source: org_study_id